Skip to content
Utilizing Advanced Tools to Minimize the Burden of CMV in Transplant Recipients
Pre-Activity Survey
Pre-Test
1.
The highest risk for CMV involve which type of transplantation serologic status?
D+/R+
D+/R-
D-/R+
All of the above are at similar risk
2.
Which of the following statements is false regarding the antiviral prophylaxis approach to preventing CMV post-transplantation?
Clinical trials demonstrate success of prophylaxis in preventing CMV.
Drug toxicity is a concern with currently available antiviral agents.
Viremia and CMV disease are rare once prophylaxis is discontinued.
Extending prophylaxis to 6 months can reduce the incidence of late-onset CMV disease when compared to 3 months of prophylaxis.
3.
Laboratory methods that can be used to assess CMV-specific cell-mediated immunity post-transplantation include all of the following except:
ELISA
ELISPOT
PCR
Cytokine flow cytometry
4.
When compared to placebo, the use of letermovir for prophylaxis in HSCT recipients has demonstrated:
Significant reduction in CMV infection
Significant reduction in all-cause mortality
Significant reduction in both CMV infection and all-cause mortality
Significant increase in graft-versus-host disease
5.
A major risk factor for CMV resistance is:
Prolonged exposure to ganciclovir/valganciclovir
Kidney transplantation
Tissue rejection within 3 months post-transplantation
Presence of graft-versus-host disease
6.
Ganciclovir resistance is commonly found in CMV strains with a mutation in:
UL54
UL97
UL128
Either UL54 or UL97